Glaxosmithkline Pharmaceuticals Ltd (GLAXO) — concall transcript | 30 June 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
GSK reported 15% YoY sales growth to ₹924 crores in Q1 FY27, with 24% PAT growth and 7% innovation revenue contribution.
🔄 What Changed
24% PAT growth and 7% innovation revenue contribution
🔮 What's Next
INR8,000 crores revenue target in 4-5 years
💡 Investor Takeaway
GSK is prioritizing sustainable double-digit growth through innovation and market expansion, with margin normalization expected despite near-term investment pressures.

GlaxoSmithKline Pharmaceuticals reported 15% YoY sales growth to [amount context mismatch] crores in Q1 FY27, driven by 17% EBITDA growth and 24% PAT growth (27.6% margin), with innovation contributing 7% of revenue. General medicines, vaccines (especially Shingrix at 65% growth), and specialty products like oncology assets showed strong momentum, while rupee depreciation and one-time dividend impacts posed challenges. Management emphasized sustainable double-digit growth, targeting INR8,000 crores revenue in 4-5 years, and highlighted pipeline launches including Arexvy and Jemperli. Operating expenses rose 36% YoY due to front-loaded investments, but margins are expected to normalize to ~34%.

📄 View Original Announcement (PDF)

About Glaxosmithkline Pharmaceuticals Ltd (GLAXO)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹51,721.36 Cr P/E: 49.2 ROE: 47.1% ROCE: 64.1% Div Yield: 1.87%

View full GLAXO stock details →

📡 Get AI alerts when GLAXO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAXO — Free

📊 More GLAXO filings

See all GLAXO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAXO files new disclosures

Track GLAXO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAXO — Free

Free account · 2 AI queries/day